fda warning bpc-157 unapproved drug 2024 warning letter Content Analysis of US Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 | Journal of Pharmaceutical Innovation Regulatory Alert: FDA's April 2026
Description
Hormone and metabolic modulators, S5
As this article is a review and does not report any new data collected by the authors, separate Institutional Review Board (IRB) or Ethics Committee approval was not sought or required for its preparation
This was a critical study for AOD 9604
Hematocrit elevation above 54 percent indicates polycythemia risk (affecting up to 20 percent of TRT patients), requiring therapeutic phlebotomy or dose reduction
